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Several decades of dengue vaccine research have shown the difficulties to develop a highly efficacious and safe vaccine that protects against all four serotypes. 1 The main challenge is the viral interference between the four serotypes in a tetravalent vaccine resulting in the potential of one serotype being immune-dominant thereby leading to an imbalanced efficacy against the remaining serotypes. 2 Imbalanced antibody levels or an imbalanced waning of protective antibody levels over time may then sensitize vaccinees to develop more severe dengue upon subsequent exposure to wild-type dengue viruses. 3 Natural studies indicate a titer-dependent and time-dependent role of cross-protective anti-dengue antibodies. 4 After an initial window of protection, cross-reactive antibodies wane from higher-titer, protective levels to lower-titer, disease-enhancing levels. 4 Using multiple statistical approaches to study a long-term pediatric cohort in Nicaragua, disease enhancement was highest within a narrow range of preexisting anti-DENV antibody titers. 5 Experiences from Cuba highlighted that the incidence of severe dengue disease increased as the interval between heterologous infections increased from 4 to 20 years. 6 Hence, longer observation times are needed to conclusively rule out an increased risk of antibody dependent enhancement in vaccine recipients. In 2012, the World Health Organization (WHO) issued guidelines on the clinical development of dengue vaccines that included a plan for follow-up of subjects for safety for at least 3-5 years from the time of completion of primary vaccination. 7 Therefore, the a priori planned longterm follow up to 6 years of the first licensed tetravalent dengue vaccine, CYD-TDV There is no need to speculate anymore. We now know the explanation. Not long after this manuscript was submitted to Clinical Microbiology and Infection, on 29 November 2017, Sanofi Pasteur made a press release highlighting new findings based on additional analyses.
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They found a significant differential performance of CYD-TDV depending on serostatus.
Serostatus refers to whether a person has experienced a dengue infection in the past; a seronegative person has not had a previous dengue infection. By utilizing a novel NS1
antibody IgG ELISA on sera obtained at month 13 of the trial, combined with imputation methods, the company retrospectively analyzed the trial data separately in participants inferred to be seronegative or seropositive at baseline to estimate the long-term safety and respectively. WHO has initiated a process engaging independent external experts to review the data in detail. This process is expected to lead to revised recommendations from SAGE in April 2018, and to an updated WHO position paper on dengue vaccine thereafter.
CYD-TDV finds itself again at a crossroad. 12 With dengue incidence poised to only increase, and highly effective vector control measures remaining elusive, the world still needs a dengue M A N U S C R I P T Will disease enhancement in seronegative vaccinees following CYC-TDV also be a problem for second-generation dengue vaccines? The answer to this question depends on the underlying mechanism of vaccine-induced enhancement observed for CYD-TDV. The most plausible hypothesis is that the live attenuated CYD-TDV initiates a first immune response to dengue in seronegative persons that predisposes them to a higher risk of severe disease. That is, the vaccine acts as a "primary-like" infection and a subsequent infection with the first wild type dengue virus is then a "secondary-like" clinically more severe infection akin to the antibody-dependent enhancement theory. 11 , 13 We do not know whether the second-generation dengue vaccines will exhibit a similar mechanism, hence we need to await the results of the two currently ongoing Phase 3 trial results for the two leading second-generation dengue vaccine candidates (one developed by Takeda 14 , and one by NIH/NIAID together with Butantan 15 ). But the bar for second-generation dengue vaccines is now clearly higher than ever before. WHO convened a technical consultation in June 2017 to guide dengue vaccine developers on trial design and duration of observation to enable broader public health recommendations for secondgeneration dengue vaccines. 7 The clinical development of second generation vaccines would be greatly facilitated if we had established correlates of protection 16 , and the lessons from CYD-TDV are that we need to study both correlates of protection and correlates of enhancement. 5 Disclaimer:
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